Aldeyra Therapeutics Inc. (ALDX)
Aldeyra Therapeutics Inc. (ALDX) Stock Price, Analysis & Data
| Geld | 1.14 |
| Marktkapitalisierung | 93.51 Mio |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -23.05 Mio |
| Beta | 1.20 |
| EPS (ttm) | -0.38 |
| KGV (TTM) | n/a |
| Forward-KGV | -5.64 |
| KBV (TTM) | 2.47 |
| KUV (TTM) | n/a |
| Earnings Date | Nov 4, 2026 |
| Brief | 1.6 |
| Volumen | 698,838 |
| Ø Vol. (20D) | 1,355,235 |
| Eröffnung | 1.54 |
| Vortagesschluss | 1.56 |
| Tagesspanne | 1.50 - 1.59 |
| 52-Wk Range | 1.07 - 6.17 |
| Analyst | Strong Buy |
| Kursziel | 7 (351.61%) |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. T...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Aldeyra Therapeutics 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -33.85 Mio, ein Rückgang von -39.4 %.
FinanzberichteAnalystenprognose
Laut 4 Analysten-Bewertungen ist die durchschnittliche Einschätzung für die ALDX-Aktie "Strong Buy". Das 12-Monats-Kursziel liegt bei 7, was Aufwärtspotenzial von 351.61% gegenüber dem aktuellen Kurs entspricht.
AktienprognosenGewinnüberraschung
Analysten erwarten einen Umsatz von ... Upgrade
vor 3 Monaten · Simply Wall St.
Upstart Holdings Leads These 3 Stocks Estimated To Be Trading Below Fair ValueOver the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected to grow by 17% per annum in the coming years. In th...
vor 3 Monaten · Simply Wall St.
3 Stocks That May Be Undervalued According To Analysts In May 2026Over the last 7 days, the United States market has risen by 1.1%, contributing to a remarkable 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environm...